Stress granules: Deciphering the connections to neurodegeneration

Originally aired: Thursday, 3 November 2022

Now available on demand! Please register to view.

If you’ve already registered, please click here to login to the webinar.

Sign Up:



Except for California residents:
By clicking "Register" you agree to receive occasional email or other contact from the sponsor of this webinar about their programs, products, services and other offerings. The sponsor agrees not to rent, sell, exchange, or give your information to any third party without permission. You may opt out of these emails at any time by contacting the sponsor. You also agree to receive occasional email or other contact from the Science/AAAS about their programs, products, services and other offerings. Science/AAAS agrees not to rent, sell, exchange, or give your information to any third party without permission. You may opt out of these emails at any time.

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

  Register

Overview

Stress granules (SGs) are a type of biomolecular condensate that consist of membraneless compartments formed in cells through liquid–liquid phase separation (LLPS). They have been shown to concentrate proteins such as RNA-binding proteins (RBPs) to enable biochemical reactions. When cells are exposed to acute biotic and abiotic stress, nuclear RBPs translocate to the cytoplasm and nucleate to form SGs and promote cell survival. Mutations in SG proteins, including TIA1, FUS, TDP43, and hnRNPA1, have been observed in neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), indicating a potential link between the mechanisms that regulate LLPS and disease progression. Studies suggest that the SG liquid–liquid state undergoes an aberrant phase transition to a more solid-like state, potentially leading to the formation of tau and other protein aggregates. Thus, further understanding of the mechanisms that control LLPS, such as nucleocytoplasmic transport or posttranslational modification, presents a new paradigm for aggregate formation that can lead to new, transformative therapeutics.

During the webinar, viewers will:

  • Learn about different factors influencing SG dynamics
  • Hear about recently discovered phase separation mechanisms regulating SG proteins implicated in ALS and FTD
  • Gain insight into the link between SG behavior and neurodegenerative disease.

If you’ve already registered, please click here to login to the webinar.

Presenters

Presenter
Speaker: Benjamin Wolozin, M.D., Ph.D.
Boston University Chobanian & Avedisian School of Medicine
Boston, MA
View Bio
Presenter
Speaker: Dorothee Dormann, Ph.D.
Johannes Gutenberg University
Mainz, Germany
View Bio
Presenter
Moderator: Sean Sanders, Ph.D.
Science/AAAS
Washington, DC
View Moderator Bio